|
Biomimetic Therapeutics, Inc. - Company Profile Snapshot
| Company Profile: |
Biomimetic Therapeutics, Inc. |
| Ticker: |
BMTI |
| Exchanges: |
NAS |
| 2008 Sales: |
3,148,400 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
88 |
Business Description
Biomimetic Therapeutics, Inc.. The Group's principal activity is to develop and commercialize bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. It received US marketing approval for its first product for bone regeneration in periodontal defects following completion of human clinical trials. The Group's first product GEM 21S is a fully synthetic regeneration system that combines a tissue growth factor, recombinant human Platelet-Derived Growth Factor, with a synthetic bone matrix, beta-tricalcium phosphate. Its lead product and product candidates combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. The Group operates throughout United States of America.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
